Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity

The first 6 patients will receive IPH2201, IV, at a dose of 4 mg/kg q2w x 4. Subsequent patients will be treated at a dose of 10 mg/kg q2w x 4.

After the end of treatment with IPH2201, according to standard recommendations in the relevant country .

After the standard surgery, according to standard recommendations in the relevant country